Use of theTrypanosoma cruziRecombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients
Open Access
- 1 February 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (2) , 707-712
Abstract
One of the greatest concerns in Chagas' disease is the absence of reliable methods for the evaluation of chemotherapy efficacy in treated patients. The tests available to evaluate cure after the specific treatment are the complement-mediated lysis (CoML) and flow cytometry tests, but they are not feasible for routine clinical use. In this study, we evaluated an enzyme-linked immunosorbent assay (ELISA) based on the recombinant Trypanosoma cruzi complement regulatory protein (rCRP) as a method to determine parasite clearance in comparison to the CoML and other methods such as conventional serology, hemoculture, and PCR in serum samples of 31 patients collected before and after the treatment, monitored for an average of 27.7 months after chemotherapy. The results showed that the percentage of patient samples that were positive by rCRP ELISA was reduced from 100 to 70.3, 62.5, 71.4, and 33.4% in the first, second, third, and fourth years after treatment, respectively, while the samples positive by CoML were reduced to 85.2, 81.2, 71.4, and 33.4% during the same period, demonstrating the same significant tendency in the reduction of positive samples. On the other hand, the conventional serology (CS) tests did not present this reduction. The percentage of samples positive by PCR was initially 77.4% and decreased to 55.5, 68.7, 47.7, and 50.0% at the fourth year after treatment, confirming the drastic clearance of circulating parasites after treatment. Our results strongly suggest that the rCRP ELISA was capable of detecting the early therapeutic efficacy in treated patients and confirmed its superiority over the CS tests and parasitologic methods.Keywords
This publication has 47 references indexed in Scilit:
- Trypanosoma cruziRecombinant Complement Regulatory Protein: a Novel Antigen for Use in an Enzyme-Linked Immunosorbent Assay for Diagnosis of Chagas' DiseaseJournal of Clinical Microbiology, 2002
- Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruziParasitology Research, 2002
- Evaluation of the xenodiagnosis of chronic Chagas patients infected ten years or over in an area where transmission has been interrupted - Iguatama and Pains, west Minas Gerais State, BrazilMemórias do Instituto Oswaldo Cruz, 1991
- Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas' diseaseMolecular and Biochemical Parasitology, 1991
- Isolamento de amostras do Trypanosoma cruzi por xenodiagnóstico e hemocultura de pacientes na fase crônica da doença de ChagasMemórias do Instituto Oswaldo Cruz, 1989
- Sensitive detection and schizodeme classification of Trypanosoma cruzi cells by amplification of kinetoplast minicircle DNA sequences: use in diagnosis of Chagas' diseaseMolecular and Biochemical Parasitology, 1989
- Hemocultures for the parasitological diagnosis of human chronic Chagas' diseaseRevista da Sociedade Brasileira de Medicina Tropical, 1989
- Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes.Journal of Experimental Medicine, 1987
- Criterion of cure of human Chagas' disease after specific chemotherapy: recent advancesMemórias do Instituto Oswaldo Cruz, 1984
- Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982